文献速递消化道肿瘤与早癌消化内镜

定量粪便免疫化学检测值在平均风险结直肠癌筛查阳性患者风险分层中的应用

Utility of Quantitative Fecal Immunochemical Test Values for Average Risk Colorectal Cancer Screening Risk Stratification Among Patients With a Positive Test.
PubMed 文献 · Am J Gastroenterol · 2025-10-22

该研究纳入2013-2022年50-75岁粪便免疫化学检测(FIT)阳性(≥20 μg/g)且12个月内接受结肠镜检查的患者,评估定量FIT值(qFIT)与结肠镜最进展发现的关系。结果显示qFIT值越高,结直肠癌和进展期腺瘤的阳性预测值越高,但肿瘤性病变可见于整个qFIT值范围,所有阳性者仍需结肠镜检查。

要点

  • qFIT值升高与结直肠癌和进展期腺瘤的阳性预测值增加相关。
  • 结直肠癌和进展期腺瘤可见于整个qFIT值范围,所有阳性者均应接受结肠镜检查。
  • 在资源有限环境中,qFIT值可能有助于对最高风险患者进行分层。

核心结论

  • 肿瘤性病变发生于整个qFIT值范围,强调所有qFIT阳性检测均需结肠镜检查。
  • qFIT值升高与结直肠癌和进展期腺瘤的阳性预测值相关,可能有助于在资源有限环境中分层最高风险患者。

研究设计与样本

  • 研究纳入2013-2022年50-75岁FIT阳性(≥20 μg/g)且在12个月内接受结肠镜检查的患者,评估qFIT值(以20 μg/g递增)与结肠镜最进展发现的关系。

主要发现

  • 在78,555份合格FIT中,结直肠癌的中位qFIT值为147.8 μg/g,高于进展期腺瘤(52.8 μg/g)、临床显著锯齿状息肉(40.9 μg/g)、非进展期腺瘤(40.4 μg/g)和正常发现(43 μg/g)。
  • 进展期腺瘤和结直肠癌的阳性预测值随qFIT值升高而增加(P < 0.001)。
  • 结直肠癌的阳性预测值从qFIT 20-39.9 μg/g范围的0.9%(95% CI: 0.8%-1.0%)升至≥200 μg/g范围的6.7%(95% CI: 6.2%-7.2%)。
  • 进展期腺瘤的阳性预测值从qFIT 20-39.9 μg/g范围的13.4%(95% CI: 13.0%-13.7%)升至≥200 μg/g范围的20.4%(95% CI: 19.5%-21.3%)。

临床怎么用

  • 所有qFIT阳性患者均应转诊结肠镜检查,不应仅凭qFIT值决定是否转诊。
  • 在资源受限环境下,可考虑结合qFIT值对阳性患者进行风险分层,优先安排最高风险者结肠镜检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Fecal immunochemical test (FIT) for colorectal cancer (CRC) screening is interpreted qualitatively (positive/negative) by a threshold quantitative fecal hemoglobin concentration (qFIT value); patients who test positive are referred for colonoscopy. Given a small percentage of persons with a positive FIT have cancer, we evaluated whether considering qFIT value might facilitate further risk stratification among FIT-positive patients. METHODS: Among patients aged 50-75 years with a positive FIT (≥20 μg/g) in 2013-2022 who underwent colonoscopy within 12 months, we evaluated qFIT values in 20 μg/g increments in relation with the most advanced finding at colonoscopy. RESULTS: Among 78,555 eligible FITs, median qFIT values were higher for CRC (147.8 μg/g) than advanced adenoma (52.8 μg/g), clinically significant serrated polyp (40.9 μg/g), nonadvanced adenoma (40.4 μg/g), and normal findings (43 μg/g). Positive predictive values (PPVs) for advanced adenoma and CRC increased with increasing qFIT values ( P < 0.001). PPV of qFIT values for CRC increased from 0.9% (95% confidence interval [CI]: 0.8%-1.0%) to 6.7% (95% CI: 6.2%-7.2%) with concentrations in the 20-39.9 μg/g to ≥200 μg/g range. Similarly, the PPV of qFIT values for advanced adenoma increased from 13.4% (95% CI: 13.0%-13.7%) to 20.4% (95% CI: 19.5%-21.3%) with values in the 20-39.9 μg/g to ≥200 μg/g range. DISCUSSION: Neoplastic findings occurred across the whole spectrum of qFIT values, emphasizing the need for colonoscopy for all positive qFIT tests. However, increasing qFIT values correlated with the PPV for CRC and advanced adenoma and may help to stratify patients at highest risk of detecting serious neoplastic lesions in resource-constrained settings.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kang JH, Jensen CD, Merchant S, et al. Utility of Quantitative Fecal Immunochemical Test Values for Average Risk Colorectal Cancer Screening Risk Stratification Among Patients With a Positive Test. Am J Gastroenterol. 2025. PMID: 41128480. doi:10.14309/ajg.0000000000003805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。